Solanbridge Group Inc. Announces Appointment of Dr. Mark T. Cullen

HOUSTON - May 2, 2014 - PRLog -- Houston – Solanbridge Group Inc.  is pleased to announce the appointment of Dr. Mark T. Cullen to the Scientific Advisory Board of SLNX. "We are proud to announce that Dr. Mark Cullen has agreed to join our Board to develop medical products that utilize cannabidiol (“CBD”), one of the many active ingredients derived from marijuana,” stated Charles R. Shirley, Chairman of the Board and Managing Director of Solanbridge.  “Dr. Cullen’s amazing career as a medical doctor, a chemist, a researcher, and as an entrepreneur makes him uniquely qualified to develop products for Solanbridge that break new ground in the development of uses for CBD beyond the currently known uses for the treatment of brain damage, severe social anxiety, cancer, psychological disorders,” Shirley continued. “We realized that with Dr. Cullen’s physical presence in the Lake Tahoe area that this is a part of the medical marijuana business that we can take immediately to the market in Nevada and California without having an indeterminate wait for licenses or other regulatory issues,” Shirley added.  Nevada and California have already approved medical marijuana for patients.

Dr. Cullen’s resume fits nicely with the development of medical marijuana products. He is a Yale University-trained doctor and medical director, who had academic appointments at Yale University and University of Florida.  Dr. Cullen has done collaborative work with the World Health Organization (WHO), the Center for Disease Control (CDC) and the National Institute of Health (NIH).  He has been published in numerous periodicals and has contributed to an educational movie series by National Geographic.  He is an entrepreneur who has developed start-up companies and has also worked as the CEO of multiple companies both public and private.  He is an inventor who has created ultrasound desulfurization and heavy oil upgrade technology.  His work has taken him throughout the world including Saudi Arabia, UAE, India, and South America.

Solanbridge is also encouraged by the changing public opinion landscape in certain U.S. jurisdictions and the potential for legislative changes toward less regulation of medical marijuana and potentially recreational marijuana use in Nevada, Alaska, Oregon, and Rhode Island.  Medical marijuana is legal in 20 states.  There is a movement toward medical marijuana legalization in Florida and Maryland, two jurisdictions where Solanbridge has a physical presence.

The Company continues to pursue a commercial grower’s license in Province of Nova Scotia.  Plans have been developed to hire a full-time staff member to administer the application process, acquire a building, equip the building with a state-of-the-art security system, and build out all aspects of a commercial medical marijuana grower’s production facility. The MOU signed by the Company on March 29, 2014 still plans to close on time.

About Solanbridge Group Inc.

Solanbridge Group Inc. is based in Spring, Texas and is a diversified holding company looking to expand into the medical marijuana industry by developing a commercial grower’s license in the Province of Nova Scotia, Canada. Solanbridge's subsidiary, David's Steak and Seafood, in Melbourne Beach, Florida, is a classic, upscale steak house, which presents polished dining in an atmosphere of timeless elegance, offering guests the finest cuts of choice USDA meats, fresh seafood and much more.

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Contact:

For further information, please contact:

Charles R. Shirley

Solanbridge Group Inc

charles@solanbridgegroup.com

832.225.1372